Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
FOCUS DIAGNOSTICS, INC.
RANDOX LABORATORIES

Genetic Test Reveals Predisposition for Abnormal Blood Clotting

By Labmedica International staff writers
Posted on 21 Feb 2013
The non-O ABO blood type is the most important risk factor for venous thromboembolism, making up 20% of inferred risk for the condition.

Individuals with an A or B blood type have an increased risk of venous thromboembolism or blood clots in their veins and myocardial infarction compared with individuals with O blood type.

A retrospective study was carried out by scientists at the Copenhagen University Hospital (Denmark) who looked at data on 66,001 people who had been followed for 33 years from 1977 through 2010 to determine whether ABO blood type is associated with an increased risk of venous blood clots in the general population. They determined ABO genotype from single nucleotide polymorphisms (SNP) in the ABO gene. The genotypes were validated by sequencing.

The scientists also measured the following using standard hospital assays: plasma levels of total cholesterol, low-density lipoprotein cholesterol, high density lipoprotein cholesterol, platelets, mean platelet volume, leukocytes, coagulation factors (II, VII, X), international normalized ratio, activated partial thromboplastin time, high-sensitivity C-reactive protein and complement C3.

The team found that the risk increased when ABO blood type was combined with factor V Leiden R506Q genotype or prothrombin G20210A genotype. These genetic mutations were associated with an increased risk of venous thromboembolisms. This finding confirms the conclusion of other studies. The scientists also found an 11-fold increased risk of venous thromboembolism for people with the prothrombin G20210A mutation. The population attributable risk of venous thromboembolism was 20% for ABO blood type, 10% for factor V Leiden R506Q and 1% for prothrombin G20210A.

Børge G. Nordestgaard, MD, DMSc, a coauthor of the study said, "We found an additive effect of ABO blood type on risk of venous thromboembolism when combined with factor V Leiden R506Q and prothrombin G20210A; ABO blood type was the most important risk factor for venous thromboembolism in the general population." The authors concluded that ABO blood type should be considered for inclusion in genetic screening for thrombophilia. The study was published February 4, 2013, in the Canadian Medical Association Journal.

Related Links:
Copenhagen University Hospital


KARL HECHT GMBH & CO KG
MEDLAB Asia
CELLAVISION AB

Channels

Genetic Tests

view channel
Image: For each chromosome, key SNPs are displayed above the chromosome and non-key SNPs below the chromosome, enabling users to determine the accuracy of haploblock calling. SNPs failed to be called are displayed as white points in the middle of the chromosome (Photo courtesy of Illumina).

Karyomapping Proposed as Alternative to Preimplantation Genetic Diagnosis for Evaluation of IVF Embryos

British researchers have suggested that karyomapping is a viable and cost-effective method for detecting a wide range of genetic diseases in IVF (in vitro fertilization) embryos. Preimplantation Genetic... Read more

Industry News

view channel
Image: Positive case of lung tissue stained for ALK with VENTANA ALK (D5F3) CDx Assay, a companion diagnostic immunohistochemical test in the final stages of the FDA premarket approval process (Photo courtesy of Ventana Medical Systems and PRNewsFoto).

Premarket Approval Sought for CDx Test to Benefit Lung Cancer Patients

Ventana Medical Systems, Inc. (Tucson, AZ, USA) has announced its US Food & Drug Administration (FDA) final stage submission for premarket approval (PMA) of its companion diagnostic (CDx) immunohistochemistry... Read more
 

Events

05 Mar 2015 - 08 Mar 2015
18 Mar 2015 - 20 Mar 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.